Schwartz R W, Logan N M, Johnson P J, Strodel W E, Fine J G, Kazmers A, Hyde G L
Department of Surgery, University of Kentucky, Chandler Medical Center, Lexington 40536-0084.
Arch Surg. 1989 Apr;124(4):434-7. doi: 10.1001/archsurg.1989.01410040044009.
Pentoxifylline, a new trisubstituted methylxanthine derivative known for its hemorrheologic action, has been shown to improve exercise tolerance in atherosclerotic patients. We examined the responses of diabetic atherosclerotic patients to pentoxifylline administration, measured by Doppler waveform analysis and exercise tolerance. Standard exercise tolerance and Doppler waveform analytic studies of the lower extremity, specifically the right dorsalis pedis artery, were performed before and after three months of pentoxifylline administration (400 mg three times a day). The study group comprised ten subjects (six men and four women) with a mean (+/- SD) age of 60 +/- 3.3 years. Data were analyzed using a paired Student t test. All ten subjects showed a significant increase in exercise tolerance after pentoxifylline treatment. Eight of ten subjects demonstrated a significant increase in right dorsalis pedis arterial flow.
己酮可可碱是一种新型三取代甲基黄嘌呤衍生物，以其血液流变学作用而闻名，已被证明可提高动脉粥样硬化患者的运动耐量。我们通过多普勒波形分析和运动耐量来检测糖尿病动脉粥样硬化患者对己酮可可碱给药的反应。在给予己酮可可碱（每日3次，每次400mg）3个月前后，进行了标准运动耐量和下肢，特别是右足背动脉的多普勒波形分析研究。研究组包括10名受试者（6名男性和4名女性），平均（±标准差）年龄为60±3.3岁。数据采用配对学生t检验进行分析。所有10名受试者在己酮可可碱治疗后运动耐量均显著增加。10名受试者中有8名右足背动脉血流显著增加。
